ARAline Renneville

Aline Renneville

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aline Renneville has a total of 222 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deuterium labeling uncovers deregulated myeloid cell kinetics in chronic myelomonocytic leukemia

    by Gurvan Hermange, Yan Zhang, Alexandre Tribut, Margot Morabito, Dorothée Selimoglu-Buet, Valentine Marchand, Nathalie Droin, Aline Renneville, Jeffie Lafosse, Hanh Duyen Tran, et al.

  • Altérations du gène Wilms’ tumor 1 (WT1) dans les leucémies aiguës myéloïdes

    by Aline Renneville

    Le gène Wilms’ Tumor 1 (WT1), localisé en 11p13, code pour une protéine régulatrice de la transcription. Initialement découvert du fait de son altération dans la tumeur de Wilms, le gène WT1 s’est avéré être aussi impliqué dans les hémopathies malignes, en particulier les leucémies aiguës myéloïdes (LAM). Le rôle de WT1 dans les LAM a été souligné par la présence d’une surexpression de WT1 dans la majorité des LAM et de mutations de WT1 dans environ 10% des cas, mais sa contribution à la leucémogenèse reste à préciser. Evaluer la fréquence, les caractéristiques associées et l’impact pronostique des mutations de WT1 et du SNP (single nucleotide polymorphism) rs16754 de WT1 dans les LAM, et déterminer si la maladie résiduelle (minimal residual disease, MRD) utilisant l’expression de WT1 (MRD-WT1) est prédictive de l’évolution clinique. Méthodes. Les mutations des exons 7 et 9 de WT1, ainsi que le SNP rs16754, ont été recherchés sur des échantillons diagnostiques sanguins ou médullaires de 517 patients présentant une LAM de novo et traités dans les protocoles français ALFA-9801 ou ALFA-9802. L’exon 7 (incluant le SNP rs16754) et l’exon 9 de WT1 ont été amplifiés par PCR sur ADN génomique puis séquencés selon la méthode de Sanger. Les taux de transcrits de WT1 ont été quantifiés par PCR quantitative en temps réel (RQ-PCR) au diagnostic et au cours du suivi thérapeutique chez un total de 221 patients atteints de LAM et traités par chimiothérapie intensive. Résultats. Dans la cohorte du protocole ALFA-9802 (patients âgés de 15 à 50 ans), les mutations de WT1 ont été identifiées chez 14/268 (5%) patients. Les mutations de WT1 étaient associées à un âge plus jeune (p=0.02) et à la présence d’une duplication en tandem de FLT3 (p=0.03). Les patients mutés WT1 présentaient un risque de rechute accru (82% vs 46% à 4 ans, p<0.001) et une survie globale plus courte (22% vs 56% à 4 ans, p=0.01) que les patients non mutés. Au sein des LAM à caryotype normal (LAM-CN) (n=106), la présence d’une mutation de WT1 constituait un facteur défavorable indépendant pour le risque de rechute. Dans la cohorte du protocole ALFA-9801 (patients âgés de 50 à 70 ans), la fréquence des mutations de WT1 était seulement de 6/249 (2.5%). En raison du faible effectif de patients mutés, la valeur pronostique des mutations de WT1 n’a pas pu être étudiée dans cette tranche d’âge. L’allèle minoritaire du SNP rs16754 a été retrouvé chez 141/511 (28%) patients, à l’état hétérozygote (WT1AG) chez 123 (24%) patients et homozygote (WT1GG) chez 18 (4%) patients. Dans la cohorte globale ainsi que dans le sous-groupe de LAM-CN (n=208), le statut du SNP rs16754 n’a pas montré d’impact pronostique significatif sur l’évolution clinique. Au total, 80-90% des échantillons présentaient une surexpression de WT1 au diagnostic. Les taux de transcrits de WT1 au diagnostic étaient plus élevés dans les LAM avec cytogénétique favorable, c’est-à-dire t(15;17), t(8;21), ou inv(16)/t(16;16), et les LAM avec mutations de NPM1, et plus bas dans le sous-type FAB M5 et en cas de réarrangement du gène MLL. Le taux d’expression de WT1 au diagnostic n’était pas corrélé à l’évolution clinique. Après la chimiothérapie d’induction, un taux faible de MRD-WT1 était associé à un risque de rechute inférieur et une survie plus longue (p<0.001). La décroissance de la MRD-WT1 exprimée en log réduction était aussi significativement associée au risque de rechute, même après ajustement sur l’âge, la leucocytose initiale et la cytogénétique (p=0.004). En fin de consolidation, la MRD-WT1 était également prédictive du risque de rechute (p=0.004). Conclusion. Dans cette étude, les mutations de WT1 et la MRD-WT1, mais pas le SNP rs16754, sont significativement associées à l’évolution clinique dans les LAM. Ces résultats suggèrent que les mutations de WT1 et la MRD-WT1 pourraient contribuer à améliorer l’évaluation pronostique et la prise en charge thérapeutique des patients atteints de LAM.

  • Open Access

    Supplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders

    by David Fandrei, Jean Pegliasco, Florence Pasquier, Nathalie Ibrahim, Maria Kfoury, Céline Berthon, Mael Heiblig, Delphine Lebon, Ambroise Marçais, Mathieu Meunier, et al.

    Supplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders

  • Open Access

    Supplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders

    by David Fandrei, Jean Pegliasco, Florence Pasquier, Nathalie Ibrahim, Maria Kfoury, Céline Berthon, Mael Heiblig, Delphine Lebon, Ambroise Marçais, Mathieu Meunier, et al.

  • High-throughput cell viability assessment using a luminescent ATP detection assay

    by Dana Alawieh, Marion Leduc, Sebastien Nakhla, Aline Renneville, Oliver Kepp


  • Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders

    by David Fandrei, Jean Pegliasco, Florence Pasquier, Nathalie Ibrahim, Maria Kfoury, Céline Berthon, Mael Heiblig, Delphine Lebon, Ambroise Marçais, Mathieu Meunier, et al.

    Purpose: PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under the selective pressure of DNA-damaging chemotherapy. However, whether PPM1D mutations promote the development of hematologic malignancies remains unclear. Experimental Design: We characterized the clinical and genomic profiles of 112 PPM1D-mutated patients across the spectrum of myeloid disorders using a combination of bulk and single-cell analyses on diagnostic and longitudinal samples. Results: Among all patients, 78% had a history of primary cancer, with DNMT3A and TP53 being the most frequently comutated genes. In 10 patients with high-grade serous ovarian cancer, longitudinal analysis showed variable dynamics of PPM1D-mutant clones, with 81% of clones expanding during exposure to alkylating agents. Clonal hierarchy estimation revealed that 44% of patients with PPM1D-mutated AML had a PPM1D mutation in the founder clone, with rare TP53 comutations. Both patients with TP53 wild-type and TP53-mutated AML had poor overall survival. Single-cell DNA and surface protein analysis in seven patients confirmed that PPM1D mutations can arise in the founding clone and are associated with the expression of leukemic markers. Conclusions: PPM1D mutations found in clonal hematopoiesis can spontaneously regress after treatment discontinuation; however, they can also be found in the dominant clone in AML/MDS.


  • Open Access

    Targeting heterochromatin eliminates chronic myelomonocytic leukemia malignant stem cells through reactivation of retroelements and immune pathways

    by Donia Hidaoui, Audrey Porquet, Rabie Chelbi, Mathieu Bohm, Aikaterini Polyzou, Vincent Alcazer, Stéphane Depil, Aygun Imanci, Margot Morabito, Aline Renneville, et al.

    Chronic myelomonocytic leukemia (CMML) is a severe myeloid malignancy affecting the elderly, for which therapeutic options are limited. DNA hypomethylating agents (HMAs) provide transient responses, failing to eradicate the malignant clone. Hematopoietic stem cell (HSC) aging involves heterochromatin reorganization, evidenced by alterations in histone marks H3K9me2 and H3K9me3. These repressive marks together with DNA methylation are essential for suppressing transposable elements (TEs). In solid cancers, the antitumor efficacy of HMAs involves the derepression of TEs, mimicking a state of viral infection. In this study, we demonstrate a significant disorganization of heterochromatin in CMML HSCs and progenitors (HSPCs) characterized by an increase in the repressive mark H3K9me2, mainly at the level of TEs, and a repression of immune and age-associated transcripts. Combining HMAs with G9A/GLP H3K9me2 methyltransferase inhibitors reactivates these pathways, selectively targeting mutated cells while preserving wild-type HSCs, thus offering new therapeutic avenues for this severe myeloid malignancy.


  • Open Access

    Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database

    by Pierre-Marie Morice, Sabine Khalife-Hachem, Marion Sassier, Véronique Lelong-Boulouard, Alina Danu, Florence Pasquier, Aline Renneville, Charles Dolladille, Jean-Baptiste Micol


  • Open Access

    CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia

    by Paul Deschamps, Margaux Wacheux, Axel Gosseye, Margot Morabito, Arnaud Pagès, Anne-Marie Lyne, Alexia Alfaro, Philippe Rameau, Aygun Imanci, Rabie Chelbi, et al.

    Chronic myelomonocytic leukemia (CMML) is a severe myeloid malignancy with limited therapeutic options. Single-cell analysis of clonal architecture demonstrates early clonal dominance with few residual WT hematopoietic stem cells. Circulating myeloid cells of the leukemic clone and the cytokines they produce generate a deleterious inflammatory climate. Our hypothesis is that therapeutic control of the inflammatory component in CMML could contribute to stepping down disease progression. The present study explored the contribution of immature granulocytes (iGRANs) to CMML progression. iGRANs were detected and quantified in the peripheral blood of patients by spectral and conventional flow cytometry. Their accumulation was a potent and independent poor prognostic factor. These cells belong to the leukemic clone and behaved as myeloid-derived suppressor cells. Bulk and single-cell RNA-Seq revealed a proinflammatory status of iGRAN that secreted multiple cytokines of which CXCL8 was at the highest level. This cytokine inhibited the proliferation of WT but not CMML hematopoietic stem and progenitor cells (HSPCs) in which CXCL8 receptors were downregulated. CXCL8 receptor inhibitors and CXCL8 blockade restored WT HSPC proliferation, suggesting that relieving CXCL8 selective pressure on WT HSPCs is a potential strategy to slow CMML progression and restore some healthy hematopoiesis.


  • Top Cited Papers
    Open Access

    RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives

    by Dana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, Aline Renneville

    NRAS and KRAS activating point mutations are present in 10–30% of myeloid malignancies and are often associated with a proliferative phenotype. RAS mutations harbor allele-specific structural and biochemical properties depending on the hotspot mutation, contributing to variable biological consequences. Given their subclonal nature in most myeloid malignancies, their clonal architecture, and patterns of cooperativity with other driver genetic alterations may potentially have a direct, causal influence on the prognosis and treatment of myeloid malignancies. RAS mutations overall tend to be associated with poor clinical outcome in both chronic and acute myeloid malignancies. Several recent prognostic scoring systems have incorporated RAS mutational status. While RAS mutations do not always act as independent prognostic factors, they significantly influence disease progression and survival. However, their clinical significance depends on the type of mutation, disease context, and treatment administered. Recent evidence also indicates that RAS mutations drive resistance to targeted therapies, particularly FLT3, IDH1/2, or JAK2 inhibitors, as well as the venetoclax-azacitidine combination. The investigation of novel therapeutic strategies and combinations that target multiple axes within the RAS pathway, encompassing both upstream and downstream components, is an active field of research. The success of direct RAS inhibitors in patients with solid tumors has brought renewed optimism that this progress will be translated to patients with hematologic malignancies. In this review, we highlight key insights on RAS mutations across myeloid malignancies from the past decade, including their prevalence and distribution, cooperative genetic events, clonal architecture and dynamics, prognostic implications, and therapeutic targeting.